Firm News
Wiggin and Dana Represents Client Affibody AB in License and Collaboration Agreement with Chiesi Farmaceutici S.p.A
Wiggin and Dana represented its client Affibody AB (“Affibody”) in its collaboration and license agreement with Chiesi Farmaceutici S.p.A (“Chiesi Group”) to discover, develop and commercialize innovative treatments for respiratory diseases based on Affibody® molecules against undisclosed targets for respiratory diseases. Under the terms of the agreement, Affibody is eligible to receive upfront, development, regulatory and commercial milestone payments up to USD 214 million plus royalties on sales for the first program. Additionally, the agreement may be expanded to a total of three programs, in which case Affibody is eligible to receive upfront, development, regulatory and commercial milestone payments up to USD 637 million plus royalties on sales. Affibody retained the option to co-promote in the Nordic region. Partner Patti Melick and Associate Madeleine Tavcar are pleased to have had the opportunity to contribute to the success of this transaction.
To read the official press release, click here.
